Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Working Capital Changes (2019 - 2025)

Historic Other Working Capital Changes for Northwest Biotherapeutics (NWBO) over the last 10 years, with Q3 2025 value amounting to -$8000.0.

  • Northwest Biotherapeutics' Other Working Capital Changes fell 14444.44% to -$8000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$11000.0, marking a year-over-year decrease of 10476.19%. This contributed to the annual value of $64000.0 for FY2024, which is 7355.37% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Other Working Capital Changes is -$8000.0, which was down 14444.44% from $58000.0 recorded in Q2 2025.
  • Northwest Biotherapeutics' Other Working Capital Changes' 5-year high stood at $125000.0 during Q4 2023, with a 5-year trough of -$42000.0 in Q2 2021.
  • Its 5-year average for Other Working Capital Changes is $26210.5, with a median of $35000.0 in 2022.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first crashed by 17118.64% in 2021, then soared by 27500.0% in 2022.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Other Working Capital Changes stood at $27000.0 in 2021, then soared by 37.04% to $37000.0 in 2022, then skyrocketed by 237.84% to $125000.0 in 2023, then tumbled by 133.6% to -$42000.0 in 2024, then soared by 80.95% to -$8000.0 in 2025.
  • Its Other Working Capital Changes was -$8000.0 in Q3 2025, compared to $58000.0 in Q2 2025 and -$19000.0 in Q1 2025.